Showing results (141-150 of 194) with videos related to
Sort By:
Pageof 20
Liver International : Official Journal of the International Association for the Study of the Liver|February 9, 2017
Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programmeChristophe Hézode, Pascal Lebray, Victor De Ledinghen, et al.Journal of Crohn'S & Colitis|May 7, 2019
Vedolizumab Therapy is Ineffective for Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A GETAID Multicentre Cohort StudyBenedicte Caron, Laurent Peyrin-Biroulet, Benjamin Pariente, et al.Journal of Medical Genetics|January 16, 2007
Environmental influence on the worldwide prevalence of a 776C->G variant in the transcobalamin gene (TCN2)Jean-Louis Guéant, Nicodème W Chabi, Rosa-Maria Guéant-Rodriguez, et al.JHEP Reports : Innovation in Hepatology|March 20, 2023
TACE and conformal radiotherapy vs. TACE alone for hepatocellular carcinoma: A randomised controlled trialCyrille Féray, Loic Campion, Philippe Mathurin, et al.European Journal of Gastroenterology & Hepatology|August 14, 2023
Unresectable hepatocellular carcinoma at dawn of immunotherapy era: real-world data from the French prospective CHIEF cohortEric Nguyen-Khac, Pierre Nahon, Olivier Ganry, et al.Liver International : Official Journal of the International Association for the Study of the Liver|November 26, 2019
Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: A randomized studyTarik Asselah, Stanislas Pol, Christophe Hezode, et al.The Lancet. Gastroenterology & Hepatology|April 14, 2017
Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trialMarc Bourlière, Pascaline Rabiega, Nathalie Ganne-Carrie, et al.Clinics and Research in Hepatology and Gastroenterology|June 30, 2020
Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohortAnais Vallet-Pichard, Jean-Michel Correas, Celine Dorival, et al.Antiviral Therapy|June 28, 2013
Randomized study of asunaprevir plus pegylated interferon-α and ribavirin for previously untreated genotype 1 chronic hepatitis CJean-Pierre Bronowicki, Stanislas Pol, Paul J Thuluvath, et al.Journal of Hepatology|December 24, 2013
Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null responseJohn M Vierling, Mitchell Davis, Steven Flamm, et al.Pageof 20